- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02726269
Triple Therapy Versus Levofloxacin-based Therapy for Helicobacter Pylori Eradication in Mexico.
Helicobacter Pylori Eradication in Mexico With a Levofloxacin-containing Scheme Versus Clarithromycin-based Triple Therapy: a Randomized, Open-label, Non-inferiority, Phase 3b Trial.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This phase IIIb study is a prospective, open-label, randomized, parallel-group, non-inferiority efficacy and safety trial. It will be carried out at four outpatient clinics in two cities placed in Mexico (Mexico City and the town of Toluca). The study was approved by a central Ethics Committee and by COFEPRIS (Mexican Federal Commission for Sanitary Risks Protection) and will be conducted in accordance with Helsinki Declaration for the protection of human subjects and with Good Clinical Practice guidelines.
Two hundred and thirty subjects aged 18 to 65 years, with HP infection proven by endoscopic biopsy and treatment-naïve will be included in the study after signing the informed consent. They will be randomly allocated into one of two groups: Group 1 will receive clarithromycin 500 mg twice daily (bid), amoxicillin 1 g bid, and lansoprazole 30 mg bid (Pylopac®, Medix SA de CV, Mexico); Group 2 will receive azithromycin 500 mg once daily (od) (Truxa®, Laboratorios Monte Verde SA, Argentina), levofloxacin 500 mg od (Laboratorios Asofarma de México SA de CV, Mexico), and pantoprazole 80 mg od (Zoltum®, Laboratorio Monte Verde SA, Argentina). Both groups will receive the treatment for 10 days. Antibiotics will be prescribed after meals, whereas the proton-pump inhibitor will be taken in a fasting condition. No other medication will be allowed until the end of the treatment.
Subjects will be evaluated using the 13C-urea breath test (13C-UBT) four weeks after HP eradication treatment. Eradication of H. pylori will be defined as a negative 13C-UBT. No further medication will be allowed during the four weeks preceding the 13C-UBT.
Regarding safety assessment, blood samples will be collected in a central laboratory following signature of the informed consent and before treatment beginning. An additional blood sample will be drawn at the end of treatment of each group for comparison with initial results. Patient compliance and treatment-related AEs will be assessed at the end of the treatment (except whether the AE is serious, in which case it will be reported immediately and appropriate actions will be decided at that time).
All biopsies will be reviewed by a central pathologist. Endoscopic biopsies will be immediately fixed in 10% buffer formalin, embedded in paraffin, sectioned (4 mm slice thickness), and dehydrated in a series of increasing ethanol/xylol concentration. Each section will be stained with hematoxylin and eosin (H&E). The diagnosis of gastritis will be established in accordance with the updated Sydney system10. Fluorescent in situ hybridization (FISH) will be performed in all biopsies. Briefly, formalin-fixed paraffin-embedded 4-mm tissue sections will be spotted onto slides coated with poly-L-lysine and processed by hexane and ethanol. Hybridization will be done using the commercially available BACTfish H pylori combi kit (Izinta Trading Co. Ltd., Hungary). The probe for H. pylori identification (Hpy 1) (5'CACACCTGACTGACTATCCCG-3') will be labeled with fluorescein isothiocyanate (FITC) that provides a green signal, and the probes that detect the three most prevalent clarithromycin-resistance mutations (ClaR1 (A2143G) 5'CGGGGTCTTCCCGTCTt-3', ClaR2 (A2144G) 5'CGGGGCTCTCCGTCTT-3', and ClaR3 (A21443C) 5-CGGGGTCTTGCCGTCTT-3') will be labeled with red fluorochrome (Cy3). Following hybridization for 90 minutes at 46 °C, sections will be washed with wash buffer twice at 46 °C for 15 minutes. Air-dried sections will be stained with 4', 6' diamino-2-phenylindole (DAPI). Slides will be evaluated using fluorescence Nikon Eclipse 80i microscope. Pictures will be taken with a Nikon DS-Fi1 camera and processed with NIS-Elements 2.1 software.
Continuous variables will be described using means and standard deviation. Efficacy analysis will be based on H. pylori eradication rate in subjects that finished treatment as per protocol. Considering a non-inferiority approach, Group 2 will be considered not inferior to Group 1 if the upper limit of the 95% confidence interval (CI) for the difference in the eradication rate between both groups is lower than the pre-established non-inferiority margin δ = 0.12%. Such margin was selected in accordance with previously published trials performed with the reference combination.
Chi-square test and Student's t-test will be used to compare both groups regarding baseline data, eradication rate, adverse events and biochemical results for safety analysis. P value < 0.05 will be considered significant. IBM SPSS 21 will be used to perform the statistical analysis.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female adult subjects who wish to participate after signing the informed consent.
- Aged between 18 and 65 years.
- HP infection diagnosed by endoscopic gastric biopsy.
Subjects who fulfill the following HP eradication criteria according to Maastricht 3 Consensus Report:
- Non ulcer dyspepsia with gastric biopsy positive for HP infection,
- Uncomplicated duodenal ulcer (without active bleeding, perforation or stenosis) with gastric biopsy positive for HP infection,
- Uncomplicated benign gastric ulcer (without active bleeding, perforation or stenosis) with gastric biopsy positive for HP infection,
- Chronic intake of NSAIDs with gastric biopsy positive for HP infection without active gastrointestinal bleeding.
Exclusion Criteria:
- Pregnant or lactating women.
- Subjects who have previously received the PLA or CLA treatment.
- Subjects who are diagnosed by endoscopy with upper gastrointestinal bleeding secondary to active peptic ulcer (gastric or duodenal) with injuries classified in any of the following stages of the Forrest Classification: I-a (Spurting hemorrhage), I-b (Oozing hemorrhage), II-a (Visible vessel) or II-b (Adherent clot).
- Subjects who are diagnosed by endoscopy with upper gastrointestinal bleeding by erosive gastritis secondary to active NSAID with positive biopsy for HP infection and whose clinical conditions require hospitalization and / or blood transfusion.
- Subjects with psychiatric disorders including eating disorders.
- Subjects with chronic degenerative diseases including uncontrolled hepatic, renal or endocrine diseases (except diabetes controlled by oral hypoglycemic agents or controlled hypothyroidism), malabsorption or chronic diarrhea, history of seizures or epilepsy, gastric surgery or subjects with oncological diseases.
- Subjects with previous allergic reactions to any of the treatment components: Pantoprazole, Amoxicillin, Clarithromycin, Azithromycin or Levofloxacin.
- Subjects with a history of photosensitivity or tendinitis secondary to quinolones intake.
Subjects who are taking any of the following medications:
- NSAIDS: Fenbufen
- ergot
- Oral anticoagulants
- Cyclosporine
- Digoxin
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: CLA (Clarithro+Lanso+Amoxi)
Clarithromycin 500 mg bid, Lansoprazole 30 mg bid and Amoxicillin 500 bid, tablets of oral administration, during 10 days.
|
Tablets of oral administration administered to subjects randomized to this group twice daily for 10 days.
Other Names:
|
Experimental: PLA (Panto+Levoflox+Azithro)
Pantoprazole 80 mg od, Levofloxacin 500 mg od and Azithromycin 500 mg od, tablets of oral administration, during 10 days.
|
Tablets of oral administration to subjects randomized to this group once daily for 10 days.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
HP eradication rate calculated from negative 13C-urea breath tests.
Time Frame: Four weeks after the end of the allocated treatment.
|
Four weeks after the end of the allocated treatment.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Determine the frequency of Clarithromycin-resistance mutations by fluorescence in situ hybridization (FISH).
Time Frame: Within a month after taking gastric endoscopy biopsy to confirm the diagnosis of HP infection.
|
Within a month after taking gastric endoscopy biopsy to confirm the diagnosis of HP infection.
|
Compare the proportion of Clarithromycin-resistance mutations determined by FISH with the HP eradication rate calculated.
Time Frame: A week after both proportions are calculated.
|
A week after both proportions are calculated.
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage and type of Adverse Events (AEs) and Serious Adverse Events (SAEs) in each group (PLA vs CLA).
Time Frame: Up to a month after the end of both treatments.
|
Up to a month after the end of both treatments.
|
Proportion of treatments prematurely suspended due to AEs or SAEs in each group (PLA vs CLA).
Time Frame: Within ten days after each treatment is randomly allocated.
|
Within ten days after each treatment is randomly allocated.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Alma L Ladrón de Guevara, MD
Publications and helpful links
General Publications
- Cuadrado-Lavin A, Salcines-Caviedes JR, Carrascosa MF, Dierssen-Sotos T, Cobo M, Campos MR, Ayestaran B, Fernandez-Pousa A, Gonzalez-Colominas E, Aresti-Zarate S, Hernandez M, Pascual EL. Levofloxacin versus clarithromycin in a 10 day triple therapy regimen for first-line Helicobacter pylori eradication: a single-blind randomized clinical trial. J Antimicrob Chemother. 2012 Sep;67(9):2254-9. doi: 10.1093/jac/dks209. Epub 2012 Jun 11.
- Chihu L, Ayala G, Mohar A, Hernandez A, Herrera-Goepfert R, Fierros G, Gonzalez-Marquez H, Silva J. Antimicrobial resistance and characterization of Helicobacter pylori strains isolated from Mexican adults with clinical outcome. J Chemother. 2005 Jun;17(3):270-6. doi: 10.1179/joc.2005.17.3.270.
- Piaggio G, Elbourne DR, Pocock SJ, Evans SJ, Altman DG; CONSORT Group. Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA. 2012 Dec 26;308(24):2594-604. doi: 10.1001/jama.2012.87802.
- Ladron-de-Guevara L, Bornstein-Quevedo L, Gonzalez-Huezo S, Castaneda-Romero B, Costa FG, di Silvio-Lopez M. Helicobacter pylori eradication in Mexico with a levofloxacin-based scheme versus standard triple therapy: Results from an open-label, randomized, noninferiority phase iiib trial. Rev Gastroenterol Mex (Engl Ed). 2019 Jul-Sep;84(3):274-283. doi: 10.1016/j.rgmx.2018.04.005. Epub 2018 Jul 27. English, Spanish.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Gastrointestinal Diseases
- Stomach Diseases
- Gastroenteritis
- Gastritis
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antineoplastic Agents
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Anti-Bacterial Agents
- Cytochrome P-450 Enzyme Inhibitors
- Cytochrome P-450 CYP1A2 Inhibitors
- Anti-Infective Agents, Urinary
- Renal Agents
- Levofloxacin
- Ofloxacin
Other Study ID Numbers
- ASO HO 01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Helicobacter Pylori Gastritis
-
Chang Gung Memorial HospitalUnknownHelicobacter Pylori Infection | Helicobacter Gastritis | Helicobacter-Associated Pyloric UlcerTaiwan
-
Hamamatsu UniversityCompletedGastritis Associated With Helicobacter PyloriJapan
-
Instituto Ecuatoriano de Enfermedades DigestivasCompletedGastritis | Atrophic Gastritis | Helicobacter Pylori Associated GastritisEcuador
-
Immunology Research Institute in GifuDong Do Pharmaceutical Co.CompletedChronic Gastritis Caused by Helicobacter PyloriVietnam
-
Affiliated Hospital to Academy of Military Medical...Shanghai 10th People's Hospital; Sixth Affiliated Hospital, Sun Yat-sen University and other collaboratorsCompletedGastritis | Atrophic Gastritis | Helicobacter Pylori Associated GastritisChina
-
Mansoura UniversityUnknownHelicobacter Pylori | Gastric Antrum | CORPUS BIOPSIESEgypt
-
Second Affiliated Hospital, School of Medicine,...CompletedHelicobacter Pylori InfectionChina
-
Xijing Hospital of Digestive DiseasesRecruitingHelicobacter Pylori Infection | Chronic GastritisChina
-
Chinese University of Hong KongRecruitingIntestinal Metaplasia | Helicobacter Pylori | Atrophic GastritisHong Kong
-
Infan Industria Quimica Farmaceutica NacionalHospital Universitário Oswaldo CruzUnknownGastritis | Helicobacter Pylori Infection